{"id":54379,"date":"2022-01-24T13:01:21","date_gmt":"2022-01-24T12:01:21","guid":{"rendered":"https:\/\/aktuelles.uni-frankfurt.de\/?p=54379"},"modified":"2023-02-17T13:35:25","modified_gmt":"2023-02-17T12:35:25","slug":"researchers-of-the-university-of-kent-and-goethe-university-find-explanation-why-the-omicron-variant-causes-less-severe-disease","status":"publish","type":"post","link":"https:\/\/aktuelles.uni-frankfurt.de\/en\/english\/researchers-of-the-university-of-kent-and-goethe-university-find-explanation-why-the-omicron-variant-causes-less-severe-disease\/","title":{"rendered":"Researchers of the University of Kent and Goethe-University find explanation why the Omicron variant causes less severe disease"},"content":{"rendered":"
\"\"<\/a>
Image: Kateryna Kon\/Shutterstock<\/figcaption><\/figure><\/div>\n\n\n\n

A new study by researchers from the University of Kent and the Goethe University Frankfurt shows that the SARS-CoV-2 Omicron variant is less effective than Delta at blocking a cellular defence mechanism against viruses, the so-called \u201cinterferon response\u201d. Moreover, cell culture findings indicate that eight important COVID-19 drugs and drug candidates remain effective against Omicron.<\/strong><\/p>\n\n\n\n

The SARS-CoV-2 Omicron variant causes less severe disease than Delta although it is better at escaping immune protection by vaccinations and previous infections. The reasons for this have so far remained elusive.<\/p>\n\n\n\n

A new study by a research team with scientists from the University of Kent and the Goethe-University Frankfurt has now shown that Omicron variant viruses are particularly sensitive to inhibition by the so-called interferon response, an unspecific immune response that is present in all body cells. This provides the first explanation of why COVID-19 patients infected with the Omicron variant are less likely to experience severe disease.<\/p>\n\n\n\n

The cell culture study also showed that Omicron viruses remain sensitive to eight of the most important antiviral drugs and drug candidates for the treatment of COVID-19. This included<\/p>\n\n\n\n

EIDD-1931 (active metabolite of molnupiravir), ribavirin, remdesivir, favipravir, PF-07321332 (nirmatrelvir, active ingredient of paxlovid), nafamostat, camostat, and aprotinin.<\/p>\n\n\n\n

Prof Martin Michaelis, School of Bioscience, University of Kent, said: \u201cOur study provides for the first time an explanation, why Omicron infections are less likely to cause severe disease. Obviously, Omicron can in contrast to Delta not effectively inhibit the host cell interferon immune response.\u201c<\/p>\n\n\n\n

Prof. Jindrich Cinatl, Institute of Medical Virology at the Goethe-University, added: \u201cAlthough cell culture experiments do not exactly recapitulate the more complex situation in a patient, our data provide encouraging evidence that the available antiviral COVID-19 drugs are also effective against Omicron.\u201c<\/p>\n\n\n\n

<\/div>\n\n\n\n

Publication: <\/strong>Denisa Bojkova, Marek Widera, Sandra Ciesek, Mark N. Wass, Martin Michaelis, Jindrich Cinatl jr. Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant SARS-CoV-2 isolates.<\/strong> In: Cell. Res. (2022) https:\/\/doi.org\/10.1038\/s41422-022-00619-9<\/a><\/p>\n\n\n\n

<\/div>\n\n\n\n

Further information: <\/strong>The drug aprotinin inhibits entry of SARS-CoV-2 in host cells (23rd<\/sup> Nov 2020)<\/p>\n\n\n\n

\n
The drug aprotinin inhibits entry of SARS-CoV2 in host cells<\/a><\/blockquote>